MetaCap

Denali Therapeutics Inc. Company Profile

NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

18.45+0.25 (+1.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Denali Therapeutics at a glance

Denali Therapeutics Inc. (NASDAQ: DNLI) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in South San Francisco, CA. Denali Therapeutics is led by Dr. Ryan J. Watts Ph.D. and employs about 503 people. The company's shares have traded publicly since 2017.

At a market capitalization of $2.92 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001714899, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Denali Therapeutics do?

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Business description based on the company's public filings.

Company information

Legal name
Denali Therapeutics Inc.
Ticker
NASDAQ: DNLI
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Ryan J. Watts Ph.D.
Employees
503
Headquarters
161 Oyster Point Boulevard, South San Francisco, CA, United States
Phone
650 866 8547
IPO year
2017
SEC CIK
0001714899
Latest annual report
10-K · Feb 26, 2026

Companies similar to Denali Therapeutics

DNLI peer companies
CompanyPrice% ChgMarket capCompare
ADMAADMA Biologics Inc13.17-1.27%$2.92Bvs DNLI
VCELVericel Corporation57.52-1.27%$2.94Bvs DNLI
IOVAIovance Biotherapeutics Inc.6.90-5.61%$3.19Bvs DNLI
RLAYRelay Therapeutics Inc.16.12+1.32%$3.56Bvs DNLI
TARSTarsus Pharmaceuticals Inc.73.01-6.00%$3.60Bvs DNLI
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs DNLI
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs DNLI
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs DNLI

Related